Apremilast study for children with mouth ulcers from Behçet’s
Treatments studied
Part of Bones, joints & muscles, Eyes & vision, Genetic & congenital, Heart & circulation, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial studies whether apremilast can help reduce mouth ulcers in children who have Behçet’s disease or juvenile psoriatic arthritis. You may be considered if your child finished a main study and is under 18, and can safely continue treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has already completed the main study through Week 52 and is under 18 when consent is signed
- Your child’s weight fits the expected growth range for their age (BMI at least the 5th percentile)
- You can bring your child to all study visits and follow the study rules
- The study doctor feels apremilast is safe enough to continue for your child
- At the Week 52 check, your child did not answer “yes” on the mental health questions (C-SSRS)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called Hemay005 for adults with Behçet's disease who have at least two mouth sores that need treatment beyond creams or rinses. It aims to see if the drug safely reduces mouth ulcers.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
This study tests apremilast to help reduce active, recurring mouth (oral) ulcers in children with Behçet’s disease. It may help if your child has had repeated mouth ulcers despite at least one non-biologic treatment.
This study tests if ustekinumab or apremilast can help control Behçet's disease symptoms like mouth and genital ulcers, skin sores, and joint pain. It may be an option if standard treatments haven't worked well.
This Phase 3 trial tests apremilast to treat active juvenile psoriatic arthritis (joint inflammation) in children and teens. You may be able to join if your child’s condition is active despite prior treatments or if they couldn’t tolerate them.
This Phase 3 trial tests whether apremilast can reduce severe, recurring mouth ulcers compared with an inactive placebo. It aims to improve ulcer frequency and pain while carefully checking safety.
Hear when a new Behçet's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.